Afinitor and Exemestane More Than Doubles PFS, Reduces Progression Risk by 57 Percent
Investigational Drug Radium-223 Chloride Improved Overall Survival By 44 Percent
NKTR-102 Shows 29 Percent Response in Phase II Study
New Two-Step Matching Process Increases Success of Transplants
Weak Electromagnetic Fields Can Possibly Stabilize Tumors
One Flexible Sigmoidoscopy Can Reduce Risk by 31 Percent
Neurocognitive Deficits Affect Future Adult Employment
Smoking, Drinking Factors Affect Adherence to Preventive Regimen
Two Doses of the Vaccine Cervarix Can Be As Effective As Three
HPV-Positive Women Over 30 Should Be Retested Within Two Years
Clinical Trials Approved By NCI CTEP Last Month
Nucynta ER Approved For Managing Chronic Pain In Adults
Zofran Label Change Includes Warnings of QT Prolongation
Agency Approves Two Pairs Of Drugs and Diagnostic Tests
Adcetris Granted Approval For Hodgkin’s Lymphoma and ALCL
Trending Stories
- Class action complaint alleging GRAIL insider fraud resubmitted after dismissal
- Cancer centers adapt to life without site visits as NIH changes CCSG review
- GRAIL to use new study results to seek FDA approval of Galleri MCD test
- Jonathan Licht named president, chief scientific officer at Van Andel Institute
- Friends publishes three white papers ahead of annual meeting
Topics: Clinical trials on rare cancers, combination drug trials, multi-regional studies - Duke brain cancer researcher Kyle Walsh named director of NIEHS
